Mar. 1, 2022
CEO Update: ZYESAMI Clinical Trial Results (COVID-AIV) Presented at peer-reviewed Congress on Retroviruses and Opportunistic Infections
Key data from the phase 2b/3 trial of ZYESAMI vs. Placebo (COVID-AIV) for treating patients with Respiratory Failure in Critical COVID-19 were presented at the February 2022 Congress on Retroviruses and Opportunistic Infections (CROI).